^
    3ms
    ATOR-4066, a bispecific antibody targeting CD40 and CEACAM5, induces strong myeloid and T cell-dependent tumor immunity and synergizes with PD-1 blockade. (PubMed, Cancer Immunol Res)
    Finally, we demonstrate that ATOR-4066 synergizes with PD-1 blockade in vitro. In conclusion, these data provide mechanistic evidence for the proposed mode of action and support further development of ATOR-4066 in CEACAM5 expressing cancers.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    CEACAM5 (CEA Cell Adhesion Molecule 5) • CD40 (CD40 Molecule)
    |
    ATOR-4066
    over2years
    ATOR-4066, a Neo-X-Prime bispecific antibody targeting CD40 and CEA, activates myeloid cells in primary human tumors in vitro and induces anti-tumor immunity in vivo (AACR 2023)
    In vivo studies using human CD40 transgenic mice bearing CEA-transfected MC38 tumors showed superior anti-tumor effects of ATOR-4066 compared to a CD40 mAb, demonstrating the ability of ATOR-4066 to efficiently induce a tumor-targeting immune response. Overall, these data show the ability of ATOR-4066 to remodel the immune microenvironment and activate tumor-infiltrating immune cells in primary human tumors expressing CEA, demonstrating the promise of this new candidate drug for further clinical development.
    Preclinical
    |
    CEACAM5 (CEA Cell Adhesion Molecule 5) • CD40 (CD40 Molecule)
    |
    CEACAM5 expression • CD40 expression
    |
    ATOR-4066